Astrocyte dysfunction and neuronal network hyperactivity in a CRISPR engineered pluripotent stem cell model of frontotemporal dementia.
Isaac CanalsAndrea Comella-BollaEfrain Cepeda-PradoNatalia AvalianiJames A CroweLeal OburogluAndreas BruzeliusNaomi KingMaría A PajaresDolores Pérez-SalaAndreas HeuerDaniella Rylander OttossonJordi SorianoHenrik AhleniusPublished in: Brain communications (2023)
Frontotemporal dementia (FTD) is the second most prevalent type of early-onset dementia and up to 40% of cases are familial forms. One of the genes mutated in patients is CHMP2B , which encodes a protein found in a complex important for maturation of late endosomes, an essential process for recycling membrane proteins through the endolysosomal system. Here, we have generated a CHMP2B -mutated human embryonic stem cell line using genome editing with the purpose to create a human in vitro FTD disease model. To date, most studies have focused on neuronal alterations; however, we present a new co-culture system in which neurons and astrocytes are independently generated from human embryonic stem cells and combined in co-cultures. With this approach, we have identified alterations in the endolysosomal system of FTD astrocytes, a higher capacity of astrocytes to uptake and respond to glutamate, and a neuronal network hyperactivity as well as excessive synchronization. Overall, our data indicates that astrocyte alterations precede neuronal impairments and could potentially trigger neuronal network changes, indicating the important and specific role of astrocytes in disease development.
Keyphrases
- early onset
- genome editing
- endothelial cells
- crispr cas
- stem cells
- cerebral ischemia
- end stage renal disease
- embryonic stem cells
- induced pluripotent stem cells
- ejection fraction
- chronic kidney disease
- late onset
- pluripotent stem cells
- newly diagnosed
- big data
- body mass index
- spinal cord
- physical activity
- electronic health record
- cell therapy
- blood brain barrier
- weight gain
- peritoneal dialysis
- patient reported outcomes
- weight loss
- transcription factor